Activation of the tissue renin-angiotensin-aldosterone system plays a leading role in the development of visceral obesity, diabetes, and its vascular complications, which is mitigated by RAAS blockers.
Renin-angiotensin-aldosterone system (RAAS) is a major system of the human body playing a key role in the regulation of most physiological andpathological conditions, such as vascular tone, AD level, myocardial and vascular wall remodeling, development of atherosclerosis, glomerulosclerosis,and other pathologies. The discovery of local (tissue) RAAS in the late XX century gave evidence of direct synthesis of all components of this system,from renin to aldosterone, in target tissues and organs. Activation of tissue RAAS was shown to play a leading role in the evolvement of diabetic complicationsincluding cardiovascular diseases, diabetic nephropathy (DN), and retinopathy. Recent studies revealed the presence of RAAS componentsin fat and pancreas. This system is involved in the development of visceral obesity, pre-diabetes, and Type 2 diabetes. These findings are confirmedby a reduced risk of CDM2 in subjects receiving long-term therapy with RAAS blockers.
М. В. Шестакова (Wed,) conducted a review in Metabolic syndrome, diabetes mellitus, and vascular complications. RAAS blockers was evaluated. Activation of the tissue renin-angiotensin-aldosterone system plays a leading role in the development of visceral obesity, diabetes, and its vascular complications, which is mitigated by RAAS blockers.